Trillium Therapeutics Inc (TRIL) Expected to Post Earnings of -$0.42 Per Share

Wall Street brokerages expect that Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) will report earnings per share of ($0.42) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Trillium Therapeutics’ earnings, with estimates ranging from ($0.43) to ($0.40). Trillium Therapeutics reported earnings per share of ($0.51) in the same quarter last year, which would suggest a positive year over year growth rate of 17.6%. The company is expected to report its next earnings report on Friday, May 10th.

On average, analysts expect that Trillium Therapeutics will report full-year earnings of ($1.89) per share for the current financial year, with EPS estimates ranging from ($2.43) to ($1.67). For the next year, analysts anticipate that the company will post earnings of ($1.21) per share, with EPS estimates ranging from ($1.61) to ($0.74). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Trillium Therapeutics.

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last released its earnings results on Monday, March 11th. The biotechnology company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.24.

TRIL has been the subject of several recent analyst reports. Cowen reaffirmed a “buy” rating on shares of Trillium Therapeutics in a research report on Thursday, December 20th. ValuEngine raised shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd. Finally, HC Wainwright reduced their price objective on shares of Trillium Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, March 13th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Trillium Therapeutics currently has an average rating of “Hold” and a consensus target price of $4.67.

Several hedge funds have recently made changes to their positions in the company. Morgan Stanley grew its position in Trillium Therapeutics by 25.2% in the 3rd quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock valued at $2,068,000 after purchasing an additional 71,860 shares during the period. Jane Street Group LLC acquired a new stake in Trillium Therapeutics in the 4th quarter valued at $43,000. Two Sigma Investments LP acquired a new stake in Trillium Therapeutics in the 4th quarter valued at $35,000. Finally, Geode Capital Management LLC grew its position in Trillium Therapeutics by 164.0% in the 4th quarter. Geode Capital Management LLC now owns 26,627 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 16,541 shares during the period. 39.43% of the stock is owned by institutional investors.

Shares of TRIL stock opened at $0.66 on Wednesday. The company has a market cap of $10.28 million, a PE ratio of -0.28 and a beta of 2.31. Trillium Therapeutics has a 52 week low of $0.55 and a 52 week high of $7.55. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.56 and a quick ratio of 3.56.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.

Read More: Treasury Bonds

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.